FDA Approves SUBOXONE — INDIVIOR INC.

INDIVIOR INC. confirmed on Tuesday that Approval for buccal buprenorphine and naloxone (SUBOXONE) was granted on August 30, 2010, signaling a pivotal advancement in FDA-approved buccal opioid use that significantly expands market accessibility for treatment-resistant patients. The expanded delivery method for buprenorphine hydrochloride provides a critical pharmaceutical alternative to patients unable to take oral therapies, reinforcing INDIVIOR’s competitive position within the high-growth analgesic and opioid addiction treatment sectors.